Articles tagged with Immunotherapy
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
Researchers at City of Hope found that advanced colorectal cancer patients with no liver metastases respond to checkpoint inhibitors, achieving a major response in 20% of cases. In contrast, patients with liver metastases showed no positive response to immunotherapy.
Researchers have developed an immunotherapy strategy that combines three drugs to boost the immune system against tumors. The new therapy showed promising results in mice, with pancreatic tumors shrinking or disappearing completely in about half of the animals.
A comprehensive molecular map of lung squamous cell carcinoma has identified potential new drug targets, including the gene NSD3, and highlighted immune regulation pathways that could help cancer evade immunotherapies. The study's findings have also revealed metabolic dysregulation and crosstalk between different cellular processes.
A research team at Kansas State University is working on a three-year project to monitor a cancerous tumor's immune state to assess immunotherapy interventions. The goal is to drive more tumors into a favorable state, ultimately contributing to improved cancer immunotherapy treatment.
A big data study from UNSW Sydney found that Australian cancer patients kept up their pharmaceutical treatments during last year's COVID-19 lockdowns. The researchers attribute the good news to relatively low rates of COVID-19 infections in Australia, which minimally impacted cancer treatment patterns.
Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.
Researchers have identified a biomarker, MHC-II, that predicts response to immunotherapies in breast cancer patients. The study found that MHC-II expression is associated with response to standard chemotherapy plus durvalumab or pembrolizumab, but not to standard neoadjuvant chemotherapy alone.
Researchers found that patients with advanced bladder cancers and FGFR3 mutations respond to immunotherapy just like those without the mutation. The study's findings suggest that FGFR3-mutated tumors can benefit from immunotherapy treatment, providing a new option for patients who previously had limited treatment options.
Researchers found that combining low-dose radiation with immunotherapy significantly boosts cancer eradication rates in mice. The treatment approach triggers the immune system to attack cancer cells, even when radiation alone is too weak to destroy them.
A new study predicts patient responses to immunotherapy using tumor fragments in the lab, offering hope for personalized cancer treatment. The researchers identified specific immune cell markers that can predict treatment response and resistance.
Researchers discover pharmacological activation of p53 triggers viral mimicry response, abolishing tumor immune evasion and promoting anti-tumor immunity. The findings have potential for developing new combination therapies that can increase cancer patient access to immunotherapy.
Researchers develop a non-invasive imaging method to track IDO1 activity, providing a promising alternative to invasive biopsies. The study found that IDO1 status in the mesenteric lymph node is a surrogate marker for cancer-immune set point and predicts immunotherapeutic efficacy.
Researchers from UNIGE and Harvard Medical School have discovered the difference between desired immune responses targeting cancer cells and unwanted responses affecting healthy tissue. By understanding these differences, they aim to develop new therapeutic approaches that minimize toxic side effects and maximize treatment efficacy.
Researchers found that MET oncogene amplification creates a hostile environment for immunotherapy, making it ineffective in treating some lung cancers. A combination of a MET inhibitor and anti-PD1 immunotherapy was effective in treating cancers with MET amplification.
Researchers used machine learning to analyze tumor microenvironment and identify biomarkers that predict patient response to immunotherapy. The model outperformed current biomarkers, enabling personalized treatment and better understanding of biological mechanisms involved.
Researchers at WashU Medicine have shown that cell-based immunotherapy using natural killer cells may be effective against solid tumors, including melanoma. The therapy has been successful in treating patients with recurrent leukemia and other blood cancers.
Researchers have developed an anti-cancer prodrug that targets cancer cells while minimizing toxicity to normal cells. This innovation improves the effectiveness of immunotherapy by boosting patient immunity. The drug exhibits anticancer effects when activated in cancer cells, inducing an active anticancer immune response.
A recent study published in the Oncogene Journal revealed that targeting HIF-1α significantly inhibited melanoma growth and amplified immune cell infiltration into tumour microenvironment. The discovery provides a valuable new target for making resistant melanomas more vulnerable to available anti-cancer treatments.
Researchers developed a microparticle-based cancer vaccine that kickstarts an immune response, increasing the proportion of mice cured of tumors to 75%. Combining the vaccine with immune checkpoint inhibitors greatly improves treatment success, offering a promising approach to improving cancer treatment.
Researchers at Michigan Medicine identified a long noncoding RNA, LIMIT, that promotes the body's immune response against cancer. By activating key genes and pathways, LIMIT boosts T cell infiltration into tumors, offering new potential therapeutic approaches to overcome immune evasion in human cancers.
Cancer immunotherapy using acoustics-based therapies has shown synergistic effects, enhancing the autogenous immune response to cancer tissue. Detailed mechanisms of sonopyrolysis-, sonoporation-, and sonoluminescence-based therapy are discussed to demonstrate its potential in cancer treatment.
Researchers found that patients with high levels of PDL-1 and a KRAS gene mutation lived longer when treated with immunotherapy alone compared to those without the mutation. Patients without the mutation had better survival with combination therapy, suggesting preferred treatment approaches for this patient group.
A new study suggests that long-term survival data for immunotherapies should be re-analyzed for potential misinterpretation. Researchers propose an adjustment method, Cox-TEL, to correct inaccurate results based on the Cox proportional-hazards model.
A team of researchers has developed AI tools to predict which lung cancer patients will respond to immunotherapy, with the goal of improving patient outcomes and reducing costs. The study uses machine learning algorithms to analyze tissue scan patterns and identify previously unseen indicators that can inform treatment decisions.
Chronic side effects among melanoma survivors after anti-PD-1 immunotherapy treatment are more common than previously recognized, affecting 43% of patients. The most frequently affected organs were joints and the endocrine system.
A Mount Sinai study found immunotherapy to be significantly less effective in liver cancer patients with non-alcoholic steatohepatitis (NASH), while also fueling tumor growth. The research highlights the need for refined therapeutic strategies to treat both tumors and underlying liver disease.
Research found that immunotherapy using checkpoint inhibitors does not benefit patients with NASH-related liver cancer, and may even promote tumor growth. The study identified a biomarker to assess treatment efficacy in these patients.
Researchers at UCLA discovered that deactivating a specific gene in cancer cells can significantly slow tumor growth and enhance the effectiveness of immunotherapy. The findings hold promise for developing more effective treatments for highly invasive head and neck squamous cell cancers.
Researchers have discovered that bacteria residing within tumor cells can be harnessed to provoke an immune reaction against the tumor. The findings suggest that bacterial peptides presented on tumor cells can serve as potential targets for immunotherapy, enabling immune T cells to recognize and attack cancer cells more precisely.
A study analyzing 45 patients with Merkel cell carcinoma found that patients with shorter disease-free intervals and specific genetic mutations, such as ARID2 and NTRK1, may be more likely to benefit from immunotherapy. These findings could inform treatment decisions and future research.
Researchers at Moffitt Cancer Center found that sequential treatment with immunotherapy followed by BRAF and MEK inhibitors promotes anti-tumor immunity and suppresses signaling that leads to drug resistance. The study suggests that this approach may be a potential treatment option for patients with melanoma.
Researchers at Columbia University Irving Medical Center have developed a new technique that uncovers tricks cancer cells use to evade immunotherapies. The approach identified new mechanisms of resistance and validated existing ones, providing insights into why some melanoma patients don't respond to treatment.
A University of Chicago study has identified multiple targets to improve cancer therapy outcomes. By depleting Ter cells and blocking artemin signaling, researchers found enhanced control of tumor burden in mice.
A new study found that altering the gut microbiome can take a patient with advanced melanoma who has never responded to immunotherapy and convert them into responders.
Scientists at Case Western Reserve University have discovered biomarkers using AI analysis of simple tissue scans to predict which lung cancer patients will be harmed by immunotherapy. This new work builds on previous research that used AI and machine learning to identify patients who will benefit from the treatment.
Researchers have developed a comprehensive framework to classify small-cell lung cancer into four unique subtypes based on gene expression. The study identifies potential therapeutic targets for each type, including an inflamed group that tends to be more responsive to immunotherapy.
Researchers found that mice with different types of T cells responded differently to tumors, with some rejecting them and others succumbing to development. The study aims to develop more effective personalized immunotherapy for cancer patients by understanding the role of T cells in immune response variation.
A recent study found that recurrent glioblastoma tumors with few mutations respond best to immunotherapy, suggesting a predictive biomarker for survival. The finding could lead to new approaches to enhance the effectiveness of immunotherapies in treating this incurable disease.
A new study published in the Journal of Allergy and Clinical Immunology: In Practice found that exposing children to small, regular doses of peanuts can reduce the risk of severe allergic reactions. Nearly 80% of preschoolers were able to eat a full serving of peanuts without reaction, protecting them from 99% of accidental exposures.
The ESMO Immuno-Oncology Congress 2020 discussed the latest developments in cancer treatment, including adjuvant and neoadjuvant treatments, tumour microenvironments, and novel therapeutics. The event also examined the impact of COVID-19 on immunotherapy in cancer patients.
Researchers found that tumor-infiltrating lymphocytes and surface protein markers PD-1 and PD-L1 can help guide immunotherapy treatment for cutaneous angiosarcomas. The study suggests that combining immunotherapies with conventional chemotherapy may be effective in treating this rare skin cancer.
Researchers from MD Anderson Cancer Center present promising clinical data on combination therapies for patients with metastatic melanoma and advanced refractory solid tumors. The treatments showed activity in activating immune pathways, leading to antitumor responses.
Researchers found that administering immunotherapy in combination with chemotherapy earlier in the course of disease can slow cancer progression. Combining the therapies also kills myeloid-derived suppressor cells, which appear to overpower immunotherapies, thereby improving response rates.
Scientists develop a new type of cancer immunotherapy that uses nanobiologics to train the innate immune system to eliminate tumor cells. The therapy targets the bone marrow and activates trained immunity, reprogramming bone marrow progenitor cells to produce immune cells that halt cancer growth.
Researchers at Eindhoven University of Technology developed a 'nanobiologic' immunotherapy that trains the innate immune system to eliminate tumorous cells. The approach has shown promising results in mouse melanoma models and non-human primates, offering a new anti-cancer therapy.
A research team led by Marisol Soengas discovered that melanoma cells use the MIDKINE protein to evade the immune system, leading to increased resistance to immunotherapy. Blocking MIDKINE can restore normal immune function and lead to tumor attack.
Researchers at Tokyo Medical and Dental University and Harvard Medical School found that controlling the nuclear localization of PD-L1 can enhance the efficacy of immunotherapy for cancer treatment. They discovered that removal of a specific modification allows PD-L1 to enter the nucleus and regulate the immune response.
Researchers at the Walter and Eliza Hall Institute found that natural killer cells are essential for slowing small cell lung cancer's aggressive spread, while T cells do not play a significant role. Supercharging NK cells further enhances their cancer-fighting abilities, offering hope for better treatments.
Researchers developed a prognostic tool that identifies immune cell interactions with tumour cells and reports on immune-checkpoint activation status. The tool predicts which cancer patients are most likely to benefit from checkpoint inhibitor therapy, allowing clinicians to tailor treatments specifically to patients.
Researchers have identified specific bacterial species that boost T-cell immunity and improve the effectiveness of immunotherapy in treating certain cancers. The discovery may lead to new treatments by harnessing the power of the microbiome to target cancer cells.
Researchers at Weizmann Institute of Science develop new technology to see inside tens of thousands of individual cells at once, identifying a subset of innate immune cells that collaborate with cancer. This breakthrough may lead to immunotherapy treatment for cancer.
Researchers developed a noninvasive method to assess the effect of cellular immunotherapies on the tumor microenvironment, which inhibits the immune response and evades cancer treatments. Nano-radiomics combines imaging technology with radiomics to analyze changes in the TME that conventional methods cannot detect.
Researchers found that blocking the tumor-promoting protein MDM2 could boost immunotherapy's effectiveness by allowing immune cells to kill tumor cells more efficiently. The study also suggests that combining MDM2 inhibitors with immunotherapy may lead to improved treatment outcomes for patients whose tumors are predicted to undergo hy...
Researchers blocked a 'jamming signal' that prevents interleukin-18 from reaching tumors, significantly reducing their growth in mice with cancer. The treatment, developed by Yale scientists, uses a synthetic version of IL-18 that can overcome the blocking protein and increase anti-tumor responses.
Scientists at City of Hope and TGen found that circulating immune cell dynamics can inform how patients respond to immunotherapy. The study's findings highlight an important predator-prey relationship between immune cells and tumor response.
The use of CAR-T immunotherapy against acute myeloid leukemia is being reevaluated due to concerns over its impact on healthy hematopoietic stem and progenitor cells. Studies have shown that anti-CD123 CAR T-cells can inhibit normal hematopoiesis, leading to irreversible impairment in blood cell formation.
Researchers reprogrammed T-cells to recognize proteins as part of the body, preventing autoimmune diseases like multiple sclerosis. The study's findings have important implications for treating autoimmune conditions and may lead to advances in overcoming autoimmunity.
Researchers analyzed 442 AML samples to identify immune classes that predict drug resistance and response to immunotherapy. IFN-γ-dominant AML patients showed strong responses to flotetuzumab and improved survival rates, highlighting the potential for T cell-targeting therapies.
A large international trial found that pembrolizumab more than doubled the progression-free survival time of patients with a specific subtype of advanced bowel cancer, compared to chemotherapy. The treatment also showed durable benefits, with 48.3% of patients experiencing no disease progression after two years.